Research programme: cancer vaccines - RhoVac

Drug Profile

Research programme: cancer vaccines - RhoVac

Alternative Names: RV 001 - RhoVac

Latest Information Update: 08 Nov 2016

Price : $50

At a glance

  • Originator RhoVac
  • Developer Herlev Hospital; RhoVac
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Nov 2016 RhoVac plans a phase IIb trial for cancer (in ex-non small cell lung cancer) (RhoVac website, November 2016)
  • 19 Oct 2016 RhoVac receives tentative approval for a patent application covering RV 001 from European Patent Office
  • 30 Jun 2016 Preclinical development is ongoing in Denmark (RhoVac Interim Report, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top